Quantcast

Latest celiac disease Stories

2009-03-31 14:59:51

U.S. medical scientists say they've demonstrated an economic benefit to the diagnosis of celiac disease in a managed care U.S. population. The researchers at the Celiac Disease Center at Columbia University Medical Center said they determined increased awareness and diagnosis of celiac disease would benefit not only patients, but also would reduce health care costs. Celiac disease occurs in genetically susceptible individuals due to the development of an immune response to gluten, the protein...

2009-03-17 18:48:00

BALTIMORE, March 17 /PRNewswire/ -- Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate. "Our most recent Phase IIb study, the largest trial with an investigational medication conducted in patients with celiac disease, was a randomized, double-blind, placebo controlled, dose ranging, multicenter study to determine the safety, tolerance and efficacy of larazotide acetate...

2009-02-02 07:10:00

One in 133 people suffer from celiac disease ANN ARBOR, Mich., Feb. 2 /PRNewswire-USNewswire/ -- Dorothy Carpenter had stomach problems her entire life. Eating as much as a bite of bread or pasta could lead to terrible pain. Her illness went undiagnosed for years until a University of Michigan Health System physician recognized it as celiac disease. By then her long-standing condition had become an intestinal mass, a cancer that forced doctors to remove part of her small intestine. "I've...

2008-11-11 21:00:07

BALTIMORE, Nov. 11 /PRNewswire/ -- Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease. Alba has enrolled and randomized the newly diagnosed patient from Spain in an eight-week Phase IIb trial with oral larazotide acetate, a tight junction regulator, for the treatment of patients with active celiac disease (CD). The global multi-center,...

2008-10-31 06:00:04

Alvine Pharmaceuticals, a biopharmaceutical company, has announced proof of concept in a Phase I trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease. The trial results confirmed that single doses of up to 1,800mg of ALV003 were safe and tolerable in healthy volunteers. Doses at the 300mg level achieved up to a 96% reduction of gluten in a meal in the stomach at 30 minutes, and were well tolerated by patients with...

2008-10-29 09:00:08

Alvine Pharmaceuticals, Inc., today announced proof of concept in a Phase 1 Trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease. The trial results confirmed that single doses of up to 1,800 mg of ALV003 were safe and tolerable in healthy volunteers. Doses at the 300 mg level achieved up to a 96% reduction of gluten in a meal in the stomach at 30 minutes, and were well tolerated by patients with celiac disease. In...

2008-10-07 12:00:19

ORLANDO, Fla., Oct. 7 /PRNewswire/ -- Alba Therapeutics Corporation presented results from two clinical studies this week at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting. Data from study CLIN 1001-004, the first Phase IIa trial conducted in celiac disease and the first to assess the prevention of immunologic changes in celiac disease, showed that larazotide acetate (AT-1001) successfully demonstrated prevention of gluten-induced immunologic changes in celiac...

2008-10-02 18:00:30

BALTIMORE, Oct. 2 /PRNewswire/ -- Alba Therapeutics Corporation today announced the promotions of Linda Arterburn, PhD, Francisco Leon, MD, PhD, Roberto Allen, Esquire, Mark Ginski, PhD, and Kate Huber. "We are pleased to announce the promotions of several of our team members and we are fortunate to have such a fine group of talented people working here to help us develop medicines for unmet medical needs of patients with celiac disease, asthma, eye disorders, and other areas to treat...

2008-09-16 03:00:09

By Anonymous New Products * New Technology * New Services Aid in diagnosis QUANTA Lite Celiac IgA Profile is a fluorescent immunoassay for the semiquantitative detection of IgA antihuman tissue transglutaminase (h-tTG) and antideamidated gliadin peptide (DGP) antibodies, the detection of an insufficient amount of IgA, in human serum. The presence of these antibodies in conjunction with other findings aids in the diagnosis of the gluten-sensitive enteropathy celiac disease. INOVA...

2008-09-16 03:00:09

By Maher, Kevin J Between 9,000 and 4,000 BC, in the age when glaciers melted and the earth warmed, nomadic hunter-gatherers settled down to more agrarian pursuits and began to cultivate wheat as a source of food. The establishment of this behavior, as it spread from Southeast Asia throughout Europe, is considered to have contributed greatly to mankind's success. The adoption of these new foods, however, was difficult for some. For these individuals and their descendants, a genetic...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related